Investment
Features
FeesSafety
Academy
More
Pluang+

Powerfleet trades cheaply despite stable subscription growth and AI-driven product improvements.

Market News
18 Sep 2026
Seeking Alpha
View Source
Neutral
Powerfleet trades cheaply despite stable subscription growth and AI-driven product improvements.

Powerfleet operates a growing subscription-based business but currently trades at low multiples due to recent revenue guidance cuts and ongoing GAAP losses. The company focuses on recurring gross profit, expanding enterprise deployments, and a large contracted customer base, with AI enhancements helping retain clients. Management projects FY27 revenue of $470.5 million and adjusted EBITDA of $112.5 million, aiming for positive free cash flow this fiscal year despite some operational challenges. Investors should watch execution risks, especially around Treasury rollout and collections, for sustainable valuation growth.

Powerfleet's recent business update provides context for readers following technology companies. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 18, 2026 20:11 WIB: out of 150 priced US tech stocks, 92 rose and 46 fell. Notable movers include BlackBerry Limited at USD 8.06 with a 1-day change of +1.51%, Grab Holdings Ltd. at USD 2.77 with -1.42%, and VNET Group Inc at USD 6.17 with +1.31%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App